Varicella Zoster Reactivation After Cord Blood Transplantation: Comparison With Unrelated Bone Marrow Transplantation  by Asano-Mori, Y. et al.
Poster Session II S299CONCLUSIONS: CLO/BU is a mid-intensity allo HSCT regi-
men with promising anti-leukemic efficacy that seems to be well tol-
erated without significant cardiac, renal or pulmonary toxicities.
CLO/BU resulted in full engraftment by day 30 in all patients. En-
rolment is closed; data collection/analysis is ongoing to determine
the practicality of this regimen being studied in a multicenter
comparative clinical trial.
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Background:There is a need to improve the conditioning regimens
for allogeneic HSCT, reducing the regimen related toxicity while
maintaining the anti-leukemic effect. The combination of myeloa-
blative doses of intravenous busulphan (BU) with fludarabine (F)
has been utilized with an improved safety profile.
Objective:We aimed to test the efficacy and safety of this combina-
tion (BUF), with a single daily dose of BU, since prior pharmacologic
and clinical studies support its safety compared with standard 4-daily
doses.
Patients: Sixty seven consecutive adult patients undergoing HLA
identical sibling allogeneicHSCT formyeloidmalignancies were re-
cruited from eight Spanish institutions. Their main characteristics
are shown in table 1.
Table 1. Patients characteristicsPATIENTS 67
Age: median (range) years 45 (17-74)
Patients aged > 55 years 30%
Male gender 58%
DISEASE
AML 35 (52.2%)
MDS Intermediate/High risk 21 (31.3%)
Secondary AML 5 (7.5%)
Myeloproliferative disorder 6 (9%)Conditioning regimen consisted in BU, one daily IV infusion (3.2
mg/kg/d) for 4 days (total dose 12.8 mg/kg), combined with F, 40
mg/m2 daily (total dose 160 mg/m2). GVHD prophylaxis consisted
in cyclosporine and methotrexate. Antimicrobial and other support-
ive measures were followed at each institution policies. Donor graft
source was PB in 76% and BM in 24% of cases. Median CD34 cells
infused were 4.0 mill/kg (0.6-17).
Results: All but one patient engrafted, with a median of 14 days (8-
34) for 0.5 granulocytes and 12 days (7-46) for 20 platelets.Main tox-
icities (Bearman) were grade 1. Major toxicity was mucositis (Grade
2 or 3, 38%of cases). There were 3 grade-2 VOD cases (4.5%) which
resolved. Acute GVHD grade 2-4 incidence was 22%. Day-100 ac-
cumulated mortality was 4.5%. The median follow-up of this ongo-
ing study is 14 months (3-51). At the time of this interim analysis, the
relapse free survival is 79.8% and overall survival 80.7%. Major
causes of death were relapse (59%) and infection or toxicity (35%).
In conclusion, in the HLA identical allogeneic HSCT setting BUF
provides excellent tumour control and low transplant related toxicity
and mortality. In particular, the incidence of VOD is\ 5%.
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IMPACT OF INJECTION VOLUME AND INFUSION RATE IN A LARGE ANI-
MAL MODEL DESIGNED TO OPTIMIZE INTRABONE TRANSPLANTATION
OF HEMATOPOIETIC STEM CELLS
Pantin, J.M.1, Robert, H.F.2, Chen,M.Y.3, Timothy, H.2, Randall, C.R.2,
Childs, R.W.1 1National Institutes of Health, Bethesda, MD; 2National
Institutes of Health, Bethesda, MD; 3National Institutes of Health,
Bethesda, MDBackground: The intrabone (IB) route of stem cell administration
results in improved engraftment in murine models of transplanta-
tion. However, human clinical trials have yet to establish that hema-
topoietic stem cell (HSC) engraftment is improved with the use of IB
delivery. The use of IB vascular access can rapidly restore systemic
blood volume and pressure in shock situations, although this access
route can be associated with pulmonary emboli. Furthermore, both
pressure and shear stress, which have not been characterized with
conventional IB delivery techniques, may damage HSCs compro-
mising their ability to engraft. Murine models do not have compar-
ative anatomy or physiology to predict the dynamics ofHSC delivery
in humans following IB injection. In contrast, swine have similar car-
diovascular physiology and size analogous to humans and can be
used as a model to study the fluid dynamics of IB injection.
Methods: Forty-five to 60 kg domestic swine were placed under
general anesthesia with IB access of the pelvis achieved using an On-
Control driver (Vidacare). Isovue was injected into the pelvis at vary-
ing volumes and rates and the entire pelvis was imaged by 320-slice
ultrafast continuous dynamicCT (Toshiba Aquilion). Pulmonary ar-
tery, carotid artery and intramarrow cavity pressures weremonitored
continuously both during and after injection into the pelvis.
Results:Wefirst characterized the comparative vascular anatomy of
the porcine pelvis. Themajor arterial blood supply to the pelvic bone
marrow was found to arise from branches of the internal iliac artery
with venous drainage occurring through the iliac vein. IB injection of
contrast led to an immediate systemic delivery into the central ve-
nous circulation. Reducing the infusion volume and slowing the
rate of the infusion both produced smaller increases in IB marrow
pressure and post-injection peak pulmonary artery systolic pressure
(PASP).
Table 1. Post IB Injection Changes in Intramarrow pressure
and Peak PASP
D Peak PulmonaryVolume
Injected (mL)Rate
Injected
(mL/s)Number of
InfusionsD Intramarrow
Pressure
(mmHg)
Mean ± S.E.Artery Systolic
Pressure
(PASP) (mmHg)
Mean ± S.E.10 0.1 4 159.3 ± 57.7 1.5 ± 0.7
10 0.2 3 300.3 ± 149.3 3.5 ± 1.0
10 0.5 2 803.4 ± 483.0 13.0 ± 5.1
10 1.0 2 1196.0 ± 265.5 8.9 ± 9.3
10 2.5 3 1689.0 ± 116.0 2.2 ± 1.0
5 0.1 2 128.7 ± 60.2 -0.5 ± 0.4
5 0.2 2 256.7 ± 42.7 1.3 ± 1.3
5 0.5 1 802.9 6.1
5 1.0 1 1490.8 0
5 2.5 1 997.5 2Conclusions: The IB route of injection provides rapid access to the
central venous circulation. Increasing IB infusion volumes and/or IB
infusion rates led to profound increases in intramarrow pressures and
significantly increases PASP. These data suggest continuous moni-
toring of IB pressures is necessary for studies aimed at characterizing
stem cell trafficking and to optimize the retention of HSC in the
intrabone marrow space following IB injection.402
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Varicella zoster virus (VZV) infection remains an important prob-
lem after allogeneic hematopoietic stem cell transplantation, because
VZV-related complications including post-herpetic neuralgia
S300 Poster Session IIsignificantly affect the patient’s quality of life. To evaluate incidences
and outcomes of VZV reactivation after cord blood transplantation
(CBT) by comparison with those after unrelated bone marrow trans-
plantation (uBMT), we retrospectively analyzed the records of 387
adult patients who underwent CBT or uBMT for the first time at
our hospital between January, 2002 and March, 2010, and survived
more than 50 days after transplantation without lost to follow-up
or re-transplantation before day 50. All patients received long-
term prophylaxis with oral acyclovir (ACV) at 200 mg/day against
VZV reactivation. 108 patients discontinued ACV at a median of
439 days (range 42-1655 days), whereas the remaining 279 continued
it until the end of follow-up. Between 50 days and 5 years after trans-
plantation, 45 patients (32 CBT and 13 uBMT) developed VZV re-
activation at a median of 591 days (range 58-1292 days), with
a cumulative incidence of 21.5%. Although the 5-year cumulative in-
cidence of VZV reactivation tended to be higher in CBT recipients
than in uBMT recipients, the difference did not reach statistical sig-
nificance (26.8% vs. 15.0%, P5 0.14). Themedian onset of VZV re-
activation did not show a significant difference between the both
groups (549 days vs. 676 days, P5 0.60). Two patients developed lo-
calized diseases within 100 days, because of early discontinuation of
ACV. Beyond 100 days after transplantation, 31 of the 165 CBT re-
cipients (18.8%) and 12 of the 116 uBMT recipients (10.3%) devel-
oped VZV reactivation, the 5-year cumulative incidence of which
was significantly higher after CBT than after uBMT (34.1% vs.
16.3%, P 5 0.028). Although breakthrough reactivation seemed to
occur more frequent in CBT recipients (14.3% vs. 4.8%, P 5
0.11), rate of dissemination was almost similar between the both
groups (7.0% vs. 5.4%, P 5 0.55). All patients were successfully
treated with antiviral agents. No important predictors were found
to be associated with VZV reactivation after CBT, while older age
(Age . 5 50) was identified as an independent risk factor for VZV
reactivation beyond 100 days after uBMT. These findings suggested
that clinical outcomes of VZV reactivation after CBT were compa-
rable to those after uBMT, in spite of the relative higher incidence of
VZV reactivation after CBT.403
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MYELODYSPLAS-
TIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: COM-
PARISON OF SURVIVAL IN PATIENTS WITH AN AVAILABLE DONOR
COMPARED TO PATIENTS WITHOUT A DONOR IN PATIENTS UP TO
AGE 75
Field, T.L.1, Perkins, J.1, Nishihori, T.1, Pidala, J.1, Tomblyn, M.1,
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Allogeneic hematopoietic cell transplantation (HCT) remains the
only curative treatment strategy for patients with MDS or CMML.
Recent reduction of the transplant related toxicity has permitted
the expansion of empiric age limitations for HCT up to 75 years.
There has been limited comparative data onHCT focusing on donor
availability in patients with MDS/CMML. Between January 2004
and September 2009, a total of 255 new patients (NP) with a diagno-
sis of MDS or CMML were evaluated for HCT at Moffitt Cancer
Center. This report describes the outcomes of these patients with
emphasis on donor availability.
Donor Search Results:Of the 255 NP, 58 did not undergo a donor
search and not included in the survival analysis. Of the 197 patients
who had a donor search initiated, a sibling (SIB) matched unrelated
(MUD) or single HLA antigen/allele mismatch (mMUD) unrelated
adult donor was found in 173 patients and not identified in the re-
maining 24 patients. To mitigate bias due to factors giving a survival
advantage to patients who were stable enough to survive the donor
search and obtain aHCT, the survival analysis included only patients
alive 90 days after the donor search was initiated.We have identified
donors within this time frame for 99%of the patients who ever found
one, although time to transplant is longer. At the 90 days landmark,there were 164 patient in the Donor cohort, and 19 patients in the
No Donor cohort.
Donor Cohort:The median age was 56.6 yrs (18.5 – 73.5). Ninety-
seven patients (59%) were older than 55 yrs. Donors were SIB (60),
MUD (75) and mMUD (29). Median follow-up of surviving patients
is 27.7months (7.2 – 70.7).
No Donor Cohort: Median age was 57.4 yrs (32.6 – 68.1) with 12
patients (63%) older than 55 yrs. Median follow-up is 9.2 months
(1.4 – 61.5).
Outcomes: Patients with a donor had significantly improved overall
survival from time of donor search vs. patients with no donor (P 5
0.007) with 2 year OS of 48% vs. 23%, respectively.
Transplant:Of the 164 in donor group, 121 (74%) patients received
HCT. The 2-year overall survival (OS) after transplantation is sim-
ilar for SIB (51%), MUD (39%) or mMUD (68%) transplant recip-
ients (P5 0.4), and also similar by age below or above 55 years (P5
0.7). These data demonstrate that most patients with MDS or
CMML can have a suitable donor identified and proceed to HCT.
Overall survival is significantly improved for those patients who
have a suitable sibling or unrelated donor.404
RITUXIMAB IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA WITH
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To evaluate the efficacy and toxicity of RIC regimen including flu-
dara. and TBI with the introduction of rituximab for allo-HSCT, we
conducted a prospective study for CLL patients aged\ 65 years in
stage B or C in response after a salvage treatment, having a HLA
identical sibling donor. The conditioning included: rituxi-
mab375mg/m2 on day-5, fludarabine30 mg/m2 from day-4 to day-
2, TBI 2grays on day0 and rituximab500mg/m2 on day1 and day8.
Forty patients were included, 34 (85%) males and 6 females, median
age 54 years (35-65), 38 (95%) in B stage and 2 in stage C. Among 23
explored for cytogenetics, 8 were abnormal. Before transplantation,
17 patients received 2 lines treatment, 10 three lines, 13$ 5 lines. At
time of allograft, 7 (17%) patients were CR, 29 (73%) in PR and 4
(10%)\ PR, 59% were sex-mismatched. For ABO matching, 68%
were compatible, 19% major incomp. & 13% minor incopm. The
median interval diagnosis-allo-HSCTwas 58 months (6-177). Seven
(17%) patients did not receive rituximab during conditioning be-
cause the protocol did not include it at the beginning and has been
amended later.Thirty-nine (98%) patients engrafted with a median
time to neutrophils recovery of 20 days (11-70), 79% of patients
reached a total donor chimerism at day 90. Seventeen patients devel-
oped aGVHDgrade$ II (8 grII, 8 grIII & 1 grIV) with a cumulative
incidence at 3 months of 44% (36-52). The cumulative incidence of
cGVHD was, at 12 months: 29% (21-36) for lim. and ext.; at 18
months: 32% (24-40) lim. and 42% (34-50) ext.. After a median fol-
low-up of 28 months (3-71), the median OS was not reached with 5-
years probability of 55%(41-74). The median time of EFS was 30
months (15 - 70) with a 5-years probability of 46%(33-66). The cu-
mulative incidence of relapse at 1 and 3 years was 17% (11-23) and
22% (15-29) respectively. The cumulative incidence TRM at 1 and
3 years was 10% (5-15) and 27% (20-35) respectively. At the last fol-
low-up, 17 patients died, 6 due to relapse and 11 due to TRM. The
multivariate analysis showed a positive impact of rituximab on OS
and EFS [HR 5 0.1 [0-0.6] p 5 0.02 & HR 5 0.1[0-0.4] p 5
0.035 respectively.The introduction of rituximab allowed a better
outcome especially a significant reduction of incidence and severity
of acute GVHD. Nevertheless there was still a high incidence of
cGVHD, leading us to propose either to increase the number of
